The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 25, 2014

Filed:

Jul. 05, 2013
Applicant:

Biogen Idec MA Inc., Cambridge, MA (US);

Inventors:

Sha Mi, Belmont, MA (US);

Kenneth J. Rhodes, Belmont, MA (US);

R. Blake Pepinsky, Arlington, MA (US);

Assignee:

Biogen Idec MA Inc., Cambrigde, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01); C07K 14/00 (2006.01); C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 38/17 (2006.01); C07K 16/28 (2006.01); C12N 15/11 (2006.01); A61K 31/7088 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39541 (2013.01); C07K 14/00 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C12N 15/1138 (2013.01); A61K 38/00 (2013.01); A61K 31/713 (2013.01); C07K 2316/96 (2013.01); A61K 38/177 (2013.01); C07K 16/2878 (2013.01); C07K 2317/34 (2013.01); C07K 2319/30 (2013.01); C12N 15/111 (2013.01); A61K 31/7088 (2013.01); A61K 2039/505 (2013.01); C12N 2310/14 (2013.01); C07K 14/70578 (2013.01);
Abstract

The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.


Find Patent Forward Citations

Loading…